AstraZeneca Inhaler Treatment for Lung Disease Hits U.S. Setback

Date : 10/01/2019 @ 8:01AM
Source : Dow Jones News
Stock : Astrazeneca Plc (AZN)
Quote : 7258.0  29.0 (0.40%) @ 4:35PM
Astrazeneca share price Chart

AstraZeneca Inhaler Treatment for Lung Disease Hits U.S. Setback

Astrazeneca (LSE:AZN)
Historical Stock Chart

3 Months : From Sep 2019 to Dec 2019

Click Here for more Astrazeneca Charts.

By Carlo Martuscelli


AstraZeneca PLC (AZN.LN) said Tuesday that the U.S. Food and Drug Administration hadn't approved its new drug application for PT010, an inhaled treatment for chronic obstructive pulmonary disease.

The British pharmaceutical company said that the regulator issued a letter provisionally denying its request to approve the drug.

Astra said it will now work with the FDA to move the process forward by providing previously unsubmitted data which wasn't available when the first application was made.

PT010 was approved in Japan in June under the name Breztri Aerosphere, and is under regulatory review in China and the European Union.


Write to Carlo Martuscelli at


(END) Dow Jones Newswires

October 01, 2019 03:46 ET (07:46 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20191209 03:49:12